Amgen (AMGN), AstraZeneca (AZN) Report AMAGINE-2 Met Primary Endpoints
Tweet Send to a Friend
Amgen (NASDAQ: AMGN) and AstraZeneca (NYSE: AZN) announced that AMAGINE-2, a pivotal, multi-arm Phase 3 trial evaluating two doses of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
